NCAM1 supports therapy resistance and LSC function in AML
- PMID: 31122937
- DOI: 10.1182/blood-2019-03-901017
NCAM1 supports therapy resistance and LSC function in AML
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.Blood. 2019 May 23;133(21):2305-2319. doi: 10.1182/blood-2018-12-889725. Epub 2019 Feb 27. Blood. 2019. PMID: 30814062
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous